Before buying shares in the Inovio Pharmaceuticals Company you should be sure to know all the important information relative to this group as well as the data that can assist you in completing pertinent and comprehensive analyses of this company’s share price. In this dedicated article you will find all the information you require with details of the group’s activities, its major competitors on the market, and recent strategic partnerships. Of course we will also provide basic stock market data and details of the factors you should take into account for your fundamental analysis of this asset.
Firstly, regarding the activity sector in which the Inovio Pharmaceuticals Group operates, it is of course extremely important to closely follow all research and developments relating to this biotech group. In fact, it is recommended you follow attentively all the various clinical phases of candidate treatments developed as well as authorisations granted for the marketing of new treatments.
It is also important to take into account the medical sectors in which this company exercises its research activities. It is in fact possible for Inovio Pharmaceuticals to decide to enlarge its sphere of operations to touch new sectors that are highly in demand and experiencing a boost in growth.
Of course, the strategic and commercial partnerships of Inovio Pharmaceuticals will also exert a direct impact on the company’s financial situation and its profitability. We would particularly monitor its partnerships implemented with pharmaceutical laboratories.
You should also take into account movements in the financial results of the Inovio Pharmaceuticals Group as well as the strategic plans it proposes for the company’s future growth.
Finally, it is of course recommended to monitor the major competitors of this group which are mostly large biotech companies exercising their activities in the same or similar sectors, as well as monitoring their research advancements and results.
Continuing with the objective of increasing your knowledge of the Inovio Pharmaceuticals Company and its share price we now offer you the opportunity to learn more in detail about the activities exercised by this group with our detailed presentation.
The Inovio Pharmaceuticals Company is an American biotechnology group. More precisely, it is an advanced phase development biotech that participates in the perfection of immunotherapy products based on deoxyribonucleic acids, otherwise known as DNAs and vaccines for the treatment and prevention of cancers and infectious diseases.
The DNA based immunotherapies developed by the group, combined with its electroporation administrative devices, generate immune responses, notably by the lymphatic T cells, in the body with the aim of fighting the targeted illnesses.
This American biotechnology company has achieved or is currently completing clinical trial programmes on its SynCon immunotherapy relating to pre-cancers and cancers caused by the human papilloma virus or HPV, influenza, prostate cancer, breast cancer, tongue and pancreatic cancer, hepatitis C or HCV, hepatitis B or HBV, the human immunodeficiency virus otherwise known as HIV, the Ebola virus, Middle East Respiratory Syndrome, or MRS, and the Zika virus.
Through its own immunotherapy platform and due to its CELLECTRA electroporation administration technology the company boasts a portfolio of products in preclinical and clinical phase that generate immune responses in vivo. The company currently employs around 260 people.
We shall now take a few moments to briefly examine and present the major competitors of the Inovio Pharmaceuticals Group, these are primarily the other large biotech companies that also exercise activities in similar or the same sectors.
Firstly, the Evotec SE Company is a medical research and development company quoted on the stock markets of which the registered office is in Hamburg in Germany. This group exercises its activities around the world, particularly through its external partnerships with pharmaceutical and biotechnological companies, university institutions, patients defence groups and venture capital groups. Its stock market capital stands at 3.47 billion Euros with a pipeline of over a hundred programmes in partnerships in the sector of clinical discovery as well as preclinical and clinical development.
Another significant competitor is the Indian based multinational company, Alambic Pharmaceuticals. This is in fact a pharmaceutical company based in Vadodara, India. The group exercises its activities in the production of pharmaceutical products, pharmaceutical materials and substances and intermediaries. It is in fact the world leader in the sector of macrolides which are anti-infectious medicines in India.
Finally, you should also follow the EMS SA company which is the largest pharmaceutical company in Brazil and was created in 1950. This company actually operates through five divisions which include the market of ‘similars’, the generic market, the medicinal brands market, the hospitals market and the OTC medicine market. At the moment this company is present in around thirty countries through joint companies, strategic partnerships and other pharmaceutical companies.
Of course, the Inovio Pharmaceuticals group also has strategic allies that enable it to boost its growth. We offer you the opportunity here to learn about two precise examples of this type of partnership.
In 2020 the Inovio Company signed a strategic partnership agreement with the Belgian company Eurogentec, a subsidiary of the Japanese Kaneka Group. The agreement with this company specialised in the manufacture and development of biopharmaceutical products related to the manufacture of its DNA vaccine against the coronavirus. The new manufacturing site based at Liege would in fact include a new fermentation unit enabling the production of large volumes of this new generation vaccine. It should be remembered here that the Inovio Pharmaceuticals Group coordinated a worldwide coalition of collaborators, partners and investors with the aim of boosting the development of this vaccine. Following this agreement Eurogentec became a member of this consortium.
Another strategic partnership was formed with the Transgene Company and ChronTech Pharma AB with the aim of clinically testing a new vaccine therapy strategy for viral hepatitis type C in 2011. It should be remembered here that in the vaccines sector it is common procedure to follow an initial vaccination with a second using the same type of vaccine to obtain maximum effective protection against this infectious disease.
Of course, regarding the activities exercised by the biotechnology group Inovio Pharmaceuticals, it is on the Nasdaq stock market in the United States that this company’s share price is listed. More precisely, it is quoted on the Nasdaq Global Select Market. It should also be remembered here that the Inovio Pharmaceuticals Company is in fact included in the Nasdaq 100 stock market index which unites the 100 technological sector companies with the largest stock market capitals.
It is of course essential that you also complete a technical analysis of the Inovio Pharmaceuticals share price. For this you will need to use different chart indicators that are available from your online broker. Among the most popular indicators we notably find the moving averages, the support and resistance levels, the MACD indicator and the stochastic indicator. It is advisable to use several indicators to improve the accuracy of the signals thereby obtained.
It is important to closely follow the results of the different phases of clinical trials undertaken by Inovio Pharmaceuticals. To do so you can visit this biotechnological company’s official website on which the results of these trials are published in real time or you can subscribe to a personalised news feed relating to this company and its activity sector which can be found through reputable online brokers.
eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.
Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.
Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.
Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.
Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.
